image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Abstracts 
 Scientific Program 
 Photo and Film Festival 
 Exhibition 
 Contact Us 
 Personal page 
 past Guest Speakers 
       XXIX Annual Congress of the Iranian Society of Ophthalmology        بـیــست و نهمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Efficacy and Safety Non-Inferiority Comparison of Biosimilar Bevacizumab (Stivant®) to the Reference Product (Avastin®) in Patients with Prethreshold Type I Retinopathy of Prematurity
Author(s): Mojtaba Abrishami MD ; Nasser Shoeibi MD; Mohammad-Reza Ansari-Astaneh MD ; Mehdi Sakhayi MD ; Majid Abrishami MD; Seyedeh Maryam Hosseini MD
Presentation Type: Oral
Subject: Posterior Segment
Others:
Presenting Author:
Name: Mojtaba Abrishami
Affiliation :(optional) Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
E mail: mojtaba_abrishami@yahoo.com
Phone: 05138433192
Mobile: 09129377278
Purpose:

This study aimed to compare efficacy and safety of Bevacizumab (Stivant®, CinnaGen, Iran) to the innovator product (Avastin®, Genetech, South San Francisco, CA) in premature infants with prethreshold type I retinopathy of prematurity (ROP).

Methods:

In a non-inferiority case series, contralateral eye study preterm infants with bilateral type 1 ROP (zone I ROP, any stage with plus disease or zone I ROP, stage 3 without plus disease or zone 2 ROP stage 2 or 3 with plus disease ) were enrolled in this. Under topical anesthesia intravitreal bevacizumab (IVB) (0.625 mg/0.025 ml) was injected. In right eye of the patients, Stivant was injected and in the left eye Avastin was injected. Patients were followed the day after injection and weekly for 4 weeks and then biweekly till retinal vascularization became complete. Safety and efficacy of bevacizumab under each brand name in regression of disease activity (plus disease regression) and achieve complete retinal vascularization were evaluated.

Results:

Fifteen infants (nne female) with gestational age (GA) of 27.5?±?2.2 weeks and birth weight (BW) of 1202.08 ±?386.79 grams were included. IVB was performed at mean post-conceptional birth age of 34.8?±?2.9 weeks. Only one case needed laser indirect ophthalmoscopy in both eyes, two weeks after IVB. In other cases Stivant was non-inferior to Avastin in regression of plus disease, decrease in ridge height, and progress in retinal vascularization. Endophthalmitis or uveitis was not seen in each patient.

Conclusion:

Stivant® was shown to be non-inferior to Avastin® in terms of efficacy with a comparable safety profile in the treatment of prethreshold type I ROP.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات رزرو هتل
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        صفحه شخصی
        جستجوی سخنران
        تور مجازی مجتمع سپید مشهد
        آرشیو کنگره سالهای گذشته
        آرشیو سخنرانان مهمان
 
ورود شرکت کنندگان
نام کاربری :
کلمه عبور :
  کلمه عبور خود را فراموش کرده ام.
Total Visits


Congress Count Down
Today 319
Last Month 22970
Total Visitors 610774